Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer

Patrizia Ferroni, Antonella Spila, Roberta D'Alessandro, Francesca Martini, Francesca Iacovone, Giuseppe M. Ettorre, Giovanni Vennarecci, Roberto Santoro, Claudio Puoti, Fiorella Guadagni

Research output: Contribution to journalArticlepeer-review


Background: Vascular endothelial growth factor (VEGF165) is stored, transported and released by platelets. Platelet functional abnormalities have been described in patients with hepatocellular carcinoma (HCC). Thus, this study was designed to investigate the behavior of VEGF165 with respect to platelet activation in HCC. Methods: Plasma and serum VEGF165 and plasma sP-selectin levels were analyzed in patients with HCC (n=70) or cirrhosis (n=45) and control subjects (n=70). Given the thrombocytopenia that characterizes both HCC and cirrhotic patients, plasma VEGF165 and sP-selectin as well as serum VEGF (plt-VEGF165-load) levels were normalized by platelet counts. Results: Median concentrations of plasma VEGF165/platelet (p=0.002) and sP-selectin/platelet (p165/platelet at multivariate analysis (p165-load correlated with tumor diameter (p165 release by tumor in HCC. It is plt-VEGF165-load, but not plasma VEGF165 or serum VEGF165 that is an independent predictor for overall survival of HCC patients.

Original languageEnglish
Pages (from-to)450-454
Number of pages5
JournalClinica Chimica Acta
Issue number5-6
Publication statusPublished - Feb 20 2011


  • Angiogenesis
  • Hepatocellular carcinoma
  • Platelet activation
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer'. Together they form a unique fingerprint.

Cite this